• Bascones A, Tenovuo J, Ship J, Turner M, Mac Veigh I, Lopez-Ibor JM, Albi M, Lanzós E, Aliaga A. Conclusiones del Symposium 2007 de la Sociedad Española de Medi- cina Oral sobre “Xerostomía, sindrome de boca seca. Boca ardiente”. Av Odontoes- tomatol 2007,23:119-26.
• Silvestre-Donat FJ, Miralles-Jordà L, Martínez Mihi V. Tratamiento de la boca seca; puesta al día. Oral Med 2004.
• Strietzel FP, Martín-granizo R, Fedele S, Lo Russo L, Mignogna M, Reichart PA Wol- ff A. Electrostimulating device in the management of xerostomía. Oral Dis 2007; 13(2):206-13.
• Strietzel FP, Vuleti L, et al. Efficacy and safety of an intraoral electroestimulation device for xerostomia relief. A multicenter randomized trial. Arthritis Rheum 2011,63(1):180-90.
Náuseas y vómitos
• Curtis EB, Krech R, Walsh D. Common symptoms in patients with advanced cancer. J Palliat Care 1991; 7(2):25-29.
• De Conno, Caraceni A, Zecca E,Spondi E, Ventrafridda V. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointesti- nal obstruction. J Pain Symptom Manage 1991; 6:484-486.
• gupta M, Davis M, Legrand S, Walsh D, Lagman R. Nausea and vomiting in advan- ced cancer: the Cleveland Clinic protocol. J Support Oncol. 2013 Mar; 11(1):8-13. • Kris Mg, Baltzer L, Pisters KMW, Tyson LB. Enhancing the effectiveness of the specific
serotonin anatagonist. Cancer 1993; 72:3436-3442. • Licher I. Which antiemetic? J Palliat Care 1993; 9(1):42-50.
• Lichter I. Results of antiemetic management in terminal illnes. J Palliat Care 1993; 9(2):19-21.
• Mannix KA. Palliation of nausea and vomiting. En: Doyle D, Hanks gWC, MacDo- nald N (Eds.) 2nd ed. Textbook of Palliative Medicine. Oxford University Press, 1998; 489-499.
• Peroutka SJ, Snyder SH. Antiemetics: neurotransmitter binding predicts therapeutic actions. Lancet 1982; ii:658-659.
• Potanovich LM, Pisters KMW, Kris Mg, et al. Midazolam in patients receiving an- ticancer chemotherapy and antiemetics. J Pain Symptom Manage 1993; 8:519- 524.
• Schulze-Delrieu K. Metoclopramide. N Eng J Med 1981; 305:28-33.
• Tuca A. Use of granisetron transdermal system in the prevention of chemothera- py-induced nausea and vomiting: a review. Cancer Manag Res. 2009 Dec 16; 2:1-12. • Twycross Rg and Lack SA. Control of alimentary symptoms in far advanced cancer.
Churchill Livingstone, 1986; 117.
• Twycross Rg, Lack SA. Therapeutics in terminal cancer. (eds.) 2nd ed. Churchill Li- vingstone, 1990; 57.
Obstrucción intestinal maligna
• Baines M, Olivier D, Carter RL. Medical management of intestinal obstruction in pa- tients with advanced malignant desease. Lancet 1985; 2: 990-3.
• Feuer D, Broadly K. Systematic review and meta-analysis of corticosteroids for the resolution of malignat bowel obstruction in advanced gynaecologyc and gastroin- testinal cancers. Ann Oncol1999; 10: 1035-41.
Manual de
Contr
ol de síntomas
en paci
entes
con cáncer avanzado y ter
minal
after. Crit Rev Oncol Hematol. 2012 Sep; 83(3):388-92.
• Ripamonti C, Twycross R, Baines M, Bozzetti F, De Conno F, gemlo B, Hunt T, Mer- cadante S, Schaerer R, Wilkinson P. Clinical practice recommendations for manage- ment of bowel obstruction in patients with end-stage cancer. Support Care Cancer 2001; 9: 223-33.
• Tuca A, Martínez E, güell E, gómez Batiste X. Obstrucción intestinal maligan. Med Clin (Barc). 2010 Sep 11; 135(8):375-81.
• Tuca A, güell E, Martínez-Losada E, Codorniu N. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res. 2012; 4:159-69.
• Twycross R, Wilcock A. Bowel obstruction. En: Symptom Management in advanced cancer. Radcliffe Medical Press, Oxon, 2001; pp 111-5.
Caquexia-Anorexia
• Argiles JM, Álvarez B, López-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Rev. 1997; 17(5):477-98.
• granda-Cameron C, DeMille D, Lynch MP, Huntzinger C, Alcorn T, Levicoff J et al. An interdisciplinary approach to manage cancer cachexia. J Oncol Nurs. 2010 Feb; 14(1):72-80.
• Loprinzi C, Jatoi A. Pharmacologic management of cancer anorexia/cachexia. En: Hesketh PJ (Ed). UpToDate. Waltham (Massachusetts): UpToDate, 2013.
• Maddocks M, Murton AJ, Wilcock A. Therapeutic exercise in cancer cachexia. Crit Rev Oncog. 2012; 17(3):285-92.
• Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer 2010; 18:951. • Riechelmann RP, Burman D, Tannock IF, et al. Phase II trial of mirtazapine for can-
cer-related cachexia and anorexia. Am J Hosp Palliat Care 2010; 27:106.
• Ruiz garcia V, López-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2013; 3:CD004310. Ascitis
• Badosa g, gonzález-Barboteo J, Fernandez A, garzón C, Porta J. Catéteres perito- neales. Med Pal 2009; 16(2):68-71.
• Facchiano E, Risio D, Kianmanesh R, Msika S. Laparoscopic hyperthermic intraperi- toneal chemotherapy: indications, aims, and results: a systematic review of the lite- rature. Ann Surg Oncol. 2012; 19(9):2946-50.
• gishen F, Trotman I. Bedside ultrasound – experience in a palliative care unit. Euro J Cancer Care 2009; 18:642–644.
• Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEgF inhibition using bevacizumab: A potential approach for the symptomatic treatment of malignant ascites?. The Oncologist 2009; 14:1242–1251. • Mercadante S, Intravaia g, Ferrera P, Villari P, David F. Peritoneal catheter for conti- nuous drainage of ascitis in advanced cancer patients. Support Care Cancer. 2008; 16:975-978.
• Planas J, Miquel M. Insuficiencia hepática y ascitis. En: Tuca A, Libran A, Porta J (eds.) Control de síntomas digestivos en el enfermo oncológico avanzado (vol 1). Barcelo- na: Edika Med Sl, 2010; Pag 79-88.
• Smith EM, Jayson gC. The Current and Future Management of Malignant Ascites. Clin Oncol 2003, 15: 59–72.
• White MA, Agle SC, Padia RK, Zervos EE. Denver peritoneovenous shunts for the management of malignant ascites: a review of the literature in the post LeVeen Era. Am Surg. 2011; 77:1070-5.
4.
Síntomas digestivos
Disfagia
• Dobrucali A, Caglar E. Palliation of malignant esophageal obstruction and fistu- laswith self expandable metallic stents. World J Gastroenterol 2010; 16(45): 5739- 5745.
• Javed A, Pal S, Dash NR, Ahuja V, Mohanti BK, Vishnubhatla S, Sahni P, Chattopad- hyay TK. Palliative stenting with or without radiotherapy for inoperable esophage- alcarcinoma: a randomized trial. J Gastrointest Cancer 2012; 43(1):63-9. • Jiménez C, Corregidor A, gutiérrez C. Disfagia. En: Sociedad Española de ge-
riatría y gerontología. Tratado de Geriatría para residentes. Madrid: Internatio- nal Marketing & Communication, S.A. (IM&C); 2006. p. 545-553. Disponible en: http://www.segg.es/tratadogeriatria/main.html (último acceso 14 junio 2013). • Krzysztof Kujawski K, Stasiak M, Rysz J. The evaluation of esophageal stenting
complications in palliative treatment of dysphagia related to esophageal cancer. Med SciMonit, 2012; 18(5): CR323-329.
• Sreedharan A, Harris K, Crellin A, Forman D, Everett SM. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev. 2009 Oct 7; (4):CD005048. Estreñimiento
• Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The Preva- lence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1). Pain Medicine, Volume 10, Number 1, January/February 2009, pp. 35-42(8).
• Candy B, Jones L, goodman ML, Drake R, Tookman A. Laxatives or methylnal- trexone for the management of constipation in palliative care patients. Cochra- ne Database of Systematic Reviews 2011, Issue 1. Art. No.: CD003448. DOI: 10.1002/14651858.CD003448.pub3.
• Clark K, Currow DC. Constipation in Palliative Care: What Do We Use as Defini- tions and Outcome Measures. J Pain Symptom Manage. 2013 Apr; 45(4):753-62. doi: 10.1016/j.jpainsymman.2012.03.016. Epub 2012 Aug 30.
• Clark K, y cols. Exploring the relationship between the frequency of documented bowel movements and prescribed laxatives in hospitalized palliative care patients. Am J Hosp Palliat Care. 2011 Jun; 28(4):258-63. doi: 10.1177/1049909110385548. Epub 2010 Nov 7.
• Dhingra L, Shuk E, grossman B, Strada A, Wald E, Portenoy A, Knotkova H, Por- tenoy R. A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliat Med. 2013 May; 27(5):447-56. doi: 10.1177/0269216312450358. Epub 2012 Jun 15.
• goodheart CR, Leavitt SB. Managing Opioid-Induced Constipation. Pain Treat- ment Topics [special report]. 2006.
• Hawley P, Barwich D, Kirk L. Implementation of the victoria bowel performance scale. J Pain Symptom Manage. 2011 Dec; 42(6):946-53. doi:10.1016/j.jpainsym- man.2011.02.021. Epub 2011 May 26.
• Larkin PJ, Sykes NP, Centeno C, Ellershaw JE, Elsner F, Eugene B, gootjes JR, Nabal M, Noguera A, Ripamonti C, Zucco F, Zuurmond WW. European Consensus group on Constipation in Palliative Care. The management of constipation in palliative care: clinical practice recommendations. Palliative Medicine (2008); 22: 796-807. • Leppert W. Are we able to Manage Effectively Opioid-Induced Bowel Dysfunc-
tion?. J Autacoids 2012, 1:e113. doi:10.4172/2161-0479.1000e113.
• Libran A, Jiménez T, Llorens S, Rodríguez M, garzón C; Calsina A, Alisté L, Porta-Sa- les J. Factores asociados a la percepción de constipación en enfermos con cáncer avanzado. Resultados preliminares. Comunicación oral. Premio mejor comunica- ción. 8ª Congreso SECPAL. La Coruña. 2010.
Manual de
Contr
ol de síntomas
en paci
entes
con cáncer avanzado y ter
minal
• Sykes N, Thomas N. Opioid-Induced Constipation in Palliative Care - A Healthcare Professional’s Guide. www.choices-in-oic.co.uk. Set. 2008.
• Thomas JR, Karver S, Cooney gA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358:2332–43.
• Twycross R, Sykes N, Mihalyo M, Wilcock DM. Stimulant Laxatives and Opioid-In- duced Constipation. Therapeutic Reviews. AHFS 56:12. J Pain Symptom Manage. 2012 Feb; 43(6):946-53.
5
Síntomas
Respiratorios
Tos
M. Nabal Vicuña, J. Julià Torras
Definición y ePiDemiología
Expulsión súbita, ruidosa y violenta de aire de los pulmones. Se trata de una respuesta refleja o voluntaria a la irritación de la las zonas tusígenas como mecanismo de defensa del aparato respiratorio. En Cuidados Paliativos, la tos plantea problemas cuando deja su papel protector y es causa de malestar por el síntoma en sí o por empeorar otros como dolor, insomnio o ser causa de nuevos problemas: cefaleas, síncopes, fracturas, etc.Se trata de un síntoma que alcanza al 50% de los pacientes oncológicos y llega a afectar al 80% de los paciente con cáncer de pulmón o SIDA.